Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WAVECREST PMCF Study
NCT03204695Terminated
- Sponsor
- Coherex Medical
- Start
- May 2017
- Primary completion
- Jun 2018
- Countries
- 1
01
Overview
Open-label, single-arm trial, sponsored by Coherex Medical. Primary endpoint: Composite Safety Endpoint (All-cause Mortality, Pericardial Effusion Requiring Intervention, Device Embolization, Device Thrombus, Ischemic Stroke) at 45 days. Started May 2017; status: terminated.
Beyond the preview
Go deeper on NCT03204695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03204695.